Atlantic Healthcare

company

About

A rare disease pharmaceutical company acquiring, developing and commercializing therapeutics, specializing in gastroenterology.

  • 11 - 50

Details

Last Funding Type
Seed
Last Funding Money Raised
$6.80M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2006
Number Of Employee
11 - 50
Operating Status
Active

Atlantic Healthcare plc is a specialist pharmaceutical company, focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases.
Our work currently focuses on the gastrointestinal (GI) tract and targets the treatment of GI diseases, which have a debilitating effect on the lives of millions of people.

We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatments for Inflammatory Bowel Disease (IBD) and other GI diseases.

We also own the worldwide rights to renzapride, a molecule with a unique dual mode of action and the potential to treat a variety of GI motility disorders.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$56.80M
Atlantic Healthcare has raised a total of $56.80M in funding over 2 rounds. Their latest funding was raised on Jun 1, 2019 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 1, 2019 Series B $2.90M 1 Detail
Nov 1, 2016 Series B $24M 1 Detail
Jan 1, 2013 Series A $23.10M 1 Detail
Mar 1, 2007 Seed $6.80M 1 Ionis Pharmaceuticals Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Atlantic Healthcare is funded by 3 investors. Ionis Pharmaceuticals and EndoLogic USA are the most recent investors.
Investor Name Lead Investor Funding Round
Ionis Pharmaceuticals Yes Seed
EndoLogic USA Series B
Fullbrook Thorpe Investments Series B